Litigation involving US Patent 9173942

9173942

Cases

Active

2 closed

Filed

2015

Top venue

D N J Reported Variously As 3 15 Cv 08132 And 2 15 Cv 08132

1 case

Helsinn Healthcare S.A. et al. v. Qilu Pharmaceutical Co., Ltd. et al.

closed/dismissed

Docket:: 15-cv-08132
Court:: D.N.J. (reported variously as 3:15-cv-08132 and 2:15-cv-08132)
Filed:: 2015-11-17

Patents:9125905 7947724 9066980 9173942

π Helsinn Healthcare S.A.π Roche Palo Alto LLC Δ Qilu Pharmaceutical Co., Ltd.Δ Qilu Pharma, Inc.

Helsinn and Roche filed a patent-infringement action against Qilu in D.N.J. after Qilu's Paragraph IV letter regarding the '905 patent. The case was closed/dismissed, but the narrative notes uncertainty whether the '905 patent itself was pleaded; FDA's tentative-approval letter described the Qilu litigation as asserting the '724, '094, '980, and '942 patents instead.

Helsinn Healthcare S.A. et al. v. Dr. Reddy's Laboratories, Ltd. et al.

disposition unknown

Docket:: 3:15-cv-08662
Court:: U.S. District Court for the District of New Jersey (D.N.J.)
Filed:: 2015-12-15

Patents:9173942

π Helsinn Healthcare S.A.π Roche Palo Alto LLC Δ Dr. Reddy's Laboratories, Ltd.Δ Dr. Reddy's Laboratories, Inc.

DRL's 505(b)(2) NDA No. 203050 for generic palonosetron injection led to this D.N.J. action, which the PTAB identified as the district-court assertion of U.S. Patent 9,173,942. The narrative confirms the filing and '942 assertion but could not independently confirm the final disposition.